FDAsafety guidance72% confidence
FDA AP — BAXFENDY (ORIG)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as AstraZeneca.
Regulatory Analysis
Application NDA219878. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: ORIG. Review priority: PRIORITY. Active ingredients: BAXDROSTAT.
Supporting Context
- Therapeutic area
- Cardiology · ATTR-CM
- Sub-indication
- Hypertension
Related signal: AstraZeneca's Wainua fails primary endpoint in ATTR-CM Phase III trial